Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

June 14, 2024 08:00 ET | Source: Oryzon Genomics, S.A.

ORYZON Presents Preliminary Data From Ongoing Phase Ib FRIDA Trial with Iadademstat Plus Gilteritinib in Relapsed/Refractory FLT3-mut AML Patients at EHA-2024

Data from the first two cohorts demonstrated that combination of iadademstat plus gilteritinib was safe and showed strong antileukemic activityA third cohort is ongoing following FDA’s OPTIMUS...
June 03, 2024 08:00 ET | Source: Oryzon Genomics, S.A.

ORYZON Announces Journal Publication of Final Phase IIa ALICE Results with Iadademstat in The Lancet Hematology

The Phase IIa study ALICE evaluated the combination of iadademstat plus azacitidine in newly diagnosed, unfit patients with acute myeloid leukemia (AML)The combination showed substantial antileukemic...
May 30, 2024 08:00 ET | Source: Oryzon Genomics, S.A.

ORYZON to Provide Corporate Progress Updates at Several Events in June

BIO International Convention 2024European Hematology Association (EHA) 2024 European Network to Cure ALS (ENCALS) 2024 MADRID and CAMBRIDGE, Mass., May 30, 2024 (GLOBE NEWSWIRE) -- Oryzon...
May 29, 2024 08:00 ET | Source: Oryzon Genomics, S.A.

ORYZON Selected as Associated Partner in the First Important Project of Common European Interest (IPCEI) in the Health Sector (Med4Cure Project)

Commission has approved up to €1 billion of State aid by six Member States: Belgium, France, Hungary, Italy, Slovakia, and SpainOryzon to validate epigenetic agents by applying a personalized medicine...
May 09, 2024 08:00 ET | Source: Oryzon Genomics, S.A.

ORYZON to Provide Corporate Progress Updates at Several Events in May

Bio-Equity Europe 2024Asebio Investor Day 2024RSC Hot Topics: Covalent Drug DiscoveryForo Medcap BME 2024 MADRID, Spain and CAMBRIDGE, Mass., May 09, 2024 (GLOBE NEWSWIRE) -- Oryzon Genomics, S.A....
May 06, 2024 12:03 ET | Source: Oryzon Genomics, S.A.

ORYZON Reports Financial Results and Corporate Update for Quarter Ended March 31, 2024

Finalizing full data analysis from vafidemstat's PORTICO Phase IIb trial in Borderline Personality Disorder (BPD) Company planning to request an End-of-Phase II meeting with the FDA to discuss plans...
April 22, 2024 08:00 ET | Source: Oryzon Genomics, S.A.

ORYZON Secures Another Important Patent for its Lead CNS Asset, Vafidemstat

Has received “Intention to Grant” from the European Patent Office For the treatment of aggression and social withdrawal MADRID, Spain and CAMBRIDGE, Mass., April 22, 2024 (GLOBE NEWSWIRE) -- Oryzon...
April 08, 2024 08:00 ET | Source: Oryzon Genomics, S.A.

ORYZON Announces U.S. FDA Clearance of CTEP-CRADA Phase I/II Clinical Trial Sponsored by NCI for Iadademstat Plus Immune Checkpoint Inhibitors in 1L Extensive Stage Small Cell Lung Cancer

MADRID, Spain and CAMBRIDGE, Mass., April 08, 2024 (GLOBE NEWSWIRE) -- Oryzon Genomics, S.A. (ISIN Code: ES0167733015, ORY), a clinical-stage biopharmaceutical company leveraging epigenetics to...
April 05, 2024 08:00 ET | Source: Oryzon Genomics, S.A.

ORYZON to Provide Corporate Progress Updates at Several Events in April

Investing in Oncology Forum 2024Van Lanschot Kempen Life Sciences Conference Swiss Biotech Day 2024LSX World Congress MADRID, Spain and BOSTON, April 05, 2024 (GLOBE NEWSWIRE) -- Oryzon Genomics,...
February 26, 2024 14:28 ET | Source: Oryzon Genomics, S.A.

ORYZON Reports Financial Results and Corporate Update for Quarter Ended December 31, 2023

Topline data from vafidemstat's PORTICO Phase IIb trial in Borderline Personality Disorder (BPD) reported with promising results in secondary endpoints of overall severity and control of...